Gold dust in eyes might seem like an unusual therapy – but a new mouse study in the US shows the approach could potentially ...

The complete response letter did not identify any issues with the safety or efficacy of Eylea HD, Regeneron officials said.

There are adaptations and tools to help deal with low-vision issues that can result from aging and other conditions.

The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

Retinal disorders like macular degeneration and retinitis pigmentosa affect millions ... As opposed to surgery, “an ...